This review discusses the evidence in support of the use of sacubitril/valsartan for the treatment of patients with heart failure and reduced ejection fraction. Sacubitril/valsartan is the first in a new class of agents, the angiotensin receptor neprilysin inhibitors (ARNIs), which have been designed to block the renin-angiotensin-aldosterone system (RAAS) and enhance natriuretic peptides, thereby improving neurohormonal balance in patients with heart failure.
Independent expert commentary provided by Professor Andrew Sindone who director of the Heart Failure Unit and Department of Cardiac Rehabilitation at Concord Hospital in Sydney.
Please login below to download this issue (PDF)